+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Myocardial Fibrosis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830058
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 73 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Ember Therapeutics Inc
  • Galectin Therapeutics Inc
  • MandalMed Inc
  • Miragen Therapeutics Inc
  • Palatin Technologies Inc
  • MORE
High levels of pipeline activity are being observed in Myocardial Fibrosis treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Apollo Therapeutics LLC, Cytokinetics Inc, Ember Therapeutics Inc, Evotec AG , Galectin Therapeutics Inc and others.

A Significant contribution to the Myocardial Fibrosis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Myocardial Fibrosis pipeline included 17 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Myocardial Fibrosis condition and increased access to investments is encouraging growth of Myocardial Fibrosis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Myocardial Fibrosis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Myocardial Fibrosis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Myocardial Fibrosis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Myocardial Fibrosis. Further, orphan drug status, fast track designation, grants awarded and other special status for Myocardial Fibrosis pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Myocardial Fibrosis pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Myocardial Fibrosis Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Myocardial Fibrosis drugs
  • Late phase: Phase 3 and in-approval Myocardial Fibrosis drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Myocardial Fibrosis therapeutic treatment activities
Details for each Myocardial Fibrosis drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Myocardial Fibrosis therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Ember Therapeutics Inc
  • Galectin Therapeutics Inc
  • MandalMed Inc
  • Miragen Therapeutics Inc
  • Palatin Technologies Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Myocardial Fibrosis- Disease Overview
2.2 Myocardial Fibrosis- Pipeline Snapshot
2.3 Myocardial Fibrosis- Pipeline Drugs by Phase
2.4 Myocardial Fibrosis- Pipeline Drugs by Company
2.5 Myocardial Fibrosis- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Apollo Therapeutics LLC Myocardial Fibrosis Drug Pipeline, H2- 2019
3.2 Cytokinetics Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.3 Ember Therapeutics Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.4 Evotec AG Myocardial Fibrosis Drug Pipeline, H2- 2019
3.5 Galectin Therapeutics Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.6 Invivosciences Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.7 Lead Discovery Center GmbH Myocardial Fibrosis Drug Pipeline, H2- 2019
3.8 MandalMed Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.9 Merck & Co Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.10 Miragen Therapeutics Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.11 NovoMedix LLC Myocardial Fibrosis Drug Pipeline, H2- 2019
3.12 Palatin Technologies Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.13 Pharmaxis Ltd Myocardial Fibrosis Drug Pipeline, H2- 2019
3.14 ProMetic Life Sciences Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.15 Quantum Genomics Corp Myocardial Fibrosis Drug Pipeline, H2- 2019
3.16 TRACON Pharmaceuticals Inc Myocardial Fibrosis Drug Pipeline, H2- 2019
3.17 Vectus Biosystems Ltd Myocardial Fibrosis Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Myocardial Fibrosis- Phase 1 Drug Details
4.2 Myocardial Fibrosis- Phase 1 Drug Overview
4.3 Myocardial Fibrosis- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Myocardial Fibrosis- Phase 2 Drug Details
5.2 Myocardial Fibrosis- Phase 2 Drug Overview
5.3 Myocardial Fibrosis- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Myocardial Fibrosis- Phase 3 Drug Details
6.2 Myocardial Fibrosis- Phase 3 Drug Overview
6.3 Myocardial Fibrosis- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Myocardial Fibrosis- Pre-clinical Phase Drug Details
7.2 Myocardial Fibrosis- Pre-clinical Phase Drug Overview
7.3 Myocardial Fibrosis- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Apollo Therapeutics LLC
  • Cytokinetics Inc
  • Ember Therapeutics Inc
  • Evotec AG
  • Galectin Therapeutics Inc
  • Invivosciences Inc
  • Lead Discovery Center GmbH
  • MandalMed Inc
  • Merck & Co Inc
  • Miragen Therapeutics Inc
  • NovoMedix LLC
  • Palatin Technologies Inc
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Quantum Genomics Corp
  • TRACON Pharmaceuticals Inc
  • Vectus Biosystems Ltd
Note: Product cover images may vary from those shown
Adroll
adroll